Fred Hutch

Hyperthermic intraperitoneal chemotherapy offers important option for patients with peritoneal cancer

Hyperthermic intraperitoneal chemotherapy (HIPEC) provides an important treatment option that can improve survival for some patients with advanced peritoneal cancer. Managing this disease — and ...
Nature

Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review

Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is associated with poor outcome. This systematic review evaluates the available evidence about adjuvant (hyperthermic) intraperitoneal ...
Nature

Peritoneal dialysis—current status and future challenges

Peritoneal dialysis is now a well established, mature treatment modality for advanced chronic kidney disease. The medium term (at least 5 year) survival of patients on peritoneal dialysis is currently ...
ascopubs.org

Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy.

EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ...
ascopubs.org

Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer The study included 523 patients from 23 centers in four French ...
Medscape

Can Intraperitoneal Paclitaxel Improve Survival in Gastric Cancer?

Adding intraperitoneal paclitaxel to intravenous paclitaxel plus oral S-1 improved overall survival in patients with gastric cancer and peritoneal metastasis, extending median survival to 19.4 months ...